Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
Lenvatinib is used to treat progressive, differentiated thyroid cancer that can no longer be treated with radioactive iodine and has already spread to different parts of the body.
Lenvatinib is also used in combination with pembrolizumab injection as first-line treatment of advanced renal cell carcinoma (RCC), a kind of kidney cancer, in patients whose cancer has spread or cannot be removed by surgery. This medicine is also used in combination with everolimus to treat advanced kidney cancer in patients who have previously received one course of treatment with another cancer medicine.
Lenvatinib is also used to treat hepatocellular carcinoma, a type of liver cancer, that cannot be removed by surgery.
Lenvatinib is also used in combination with pembrolizumab injection to treat advanced endometrial cancer (cancer of the lining of the uterus or womb) that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), in patients who have received other cancer medicines but did not work well and cannot be removed by surgery or radiation.
Lenvatinib is an antineoplastic (cancer) medicine. It interferes with the growth of cancer cells, which are eventually destroyed by the body.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms: